ASPI

1.1003.08%
PE

Paul Elliot Mann

Executive Chairman & CEO

Mr. Paul Elliot Mann, C.F.A., is Executive Chairman of Skyline Builders Group Holding Limited from January 1, 2026. He has been the Executive Chairman of ASP Isotopes Inc. since September 2021 and served as its President until October 01, 2025 and serves as its Chief Executive Officer. He has been Independent Director at Illumination Acquisition Corp I since February 26, 2026. He co-founded ASP Isotopes Inc. in September 2021 and was its Chief Financial Officer since September 2021 until September 2022. He is President & Executive Chairman of Aeternum Resources Inc. (formerly known as Aeternum Health Inc.) from July 31, 2026. He is co-founder of Varian Biopharmaceuticals and its Chairman since June 2020. Prior to this, Mr. Mann was a consultant and analyst for DSAM Partners, a global hedge fund, from April 2020 to March 2022. He serves as Director at Healthtech Solutions Inc. since July 13, 2021 and its Chairman of the Board. Mr. Mann served as an Independent Director at Abeona Therapeutics Inc. since June 17, 2020 until May 2023. He had been Executive Officer of PolarityTE, Inc from April 2020 to September 30, 2020. He served as Chief Financial Officer of PolarityTE, Inc. from June 2018 to March 31, 2020. Mr. Mann has financial industry experience, most recently as the Healthcare Portfolio Manager at Highbridge Capital Management from August 2016 to June 2018. Mr. Mann spent 11 years as a sell-side analyst at Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Proctor and Gamble and is named as an inventor on patent applications for skincare compounds and technologies. Mr. Mann was an Executive Director at Morgan Stanley, Research Division. From August 2013 to March 2016, Mr. Mann served as an analyst with Soros Fund Management. Prior to joining Soros Fund Management, Mr. Mann was an analyst and portfolio manager with Lodestone Natural Resources and UBS from September 2011 to March 2013. He was also corporate broker to over half the UK Pharmaceutical Companies. Prior to becoming a financial analyst, Mr. Mann started his career as a Research Scientist at Procter & Gamble, where his work led to the invention of a number of patented and commercial products. He is Chartered Financial Analyst. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering.

公司职务